Unstoppable antidiabetic ‘Zemiglo’ passing KRW 7 billion prescriptions a month

‘Zemiglo,’ a novel antidiabetic developed for the first time in Korea, passed KRW 7 billion prescriptions a month.

According to UBIST, a pharmaceutical information company, LG Chem’s ‘Zemiglo’ passed KRW 7 billion outpatient prescriptions last September.

After passing KRW 6 billion on May this year, Zemiglo is having a sharp uptrend exceeding KRW 7 billion only in 4 months.

After signing a c...